XML 51 R37.htm IDEA: XBRL DOCUMENT
v3.24.3

Related Party Transactions (Details) - USD ($) |  |  |  |  |  |  |  |  | 2 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 20, 2024 | Nov. 13, 2023 | Oct. 27, 2023 | Jul. 19, 2023 | Apr. 20, 2023 | Jan. 27, 2023 | Sep. 07, 2021 | Nov. 01, 2019 | Sep. 10, 2024 | Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 19, 2023
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties on sales (in percent) |  |  |  |  |  |  |  |  |  | 70.00% |  |  |
Research and Development Costs - Related Party |  |  |  |  |  |  |  |  |  | $ 5,437,297 | $ 6,392,414 |  |
Interest expense |  |  |  |  |  |  |  |  |  | 49,808 |  |  |
Related party |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Account Payable - Related Party |  |  |  |  |  |  |  |  |  | 720,039 | 233,434 |  |
Subsequent event |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares upon principle of note convertible |  |  |  |  |  |  |  |  | 772,836 |  |  |  |
Dr. Anil Diwan | Subsequent event | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Line of credit | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Maturity of the Company's line of Credit | Dec. 31, 2025 |  |  |  |  |  |  |  |  |  |  |  |
Dr. Anil Diwan | Subsequent event | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Line of credit | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Maturity of the Company's line of Credit | Mar. 31, 2026 |  |  |  |  |  |  |  |  |  |  |  |
Line of credit agreement | Dr. Anil Diwan |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Line of Credit Facility, Maximum Borrowing Capacity |  | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |
Fixed rate of interest on the amount drawn under the line of credit facility |  | 12.00% |  |  |  |  |  |  |  |  |  |  |
Drew down amount |  |  |  |  |  |  |  |  |  | 0 |  |  |
KMPL |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical trial related and other costs |  |  |  |  |  |  |  |  |  | 442,845 | 100,000 |  |
KMPL | Related party |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued clinical trial related and other costs |  |  |  |  |  |  |  |  |  | 227,435 | 100,000 |  |
Clinical trial Costs Accrued - Related Party |  |  |  |  |  |  |  |  |  | $ 442,845 | 100,000 |  |
TheraCour Pharma Inc |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of direct costs |  |  |  |  |  |  |  |  |  | 30.00% |  |  |
Other general and administrative expense |  |  |  |  |  |  |  |  |  | $ 2,000 |  |  |
Percentage of net sales allocated for royalty payments (in percent) |  |  |  |  |  |  |  |  |  | 15.00% |  |  |
Accounts payable |  |  |  |  |  |  |  |  |  |  | 733,434 |  |
Accounts payable offset by advance |  |  |  |  |  |  |  |  |  | $ 0 | 500,000 |  |
Accrued royalties |  |  |  |  |  |  |  |  |  | 0 | 0 |  |
TheraCour Pharma Inc | Related party |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Account Payable - Related Party |  |  |  |  |  |  |  |  |  | 720,039 | 233,434 |  |
Percentage of net sales allocated for royalty payments (in percent) |  |  |  |  |  |  |  | 15.00% |  |  |  |  |
Research and Development Costs - Related Party |  |  |  |  |  |  |  |  |  | 2,550,466 | 2,535,862 |  |
Number of shares upon principle of note convertible |  |  | 331,859 |  |  |  |  |  |  |  |  |  |
Gain on extinguishment |  |  |  |  |  |  |  |  |  | $ 49,808 |  |  |
TheraCour Pharma Inc | COVID 19 License Agreement | Related party |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Costs - Related Party |  |  |  |  | $ 157,000 |  |  |  |  |  | $ 157,000 | $ 935,088 |
Milestone payment amount due |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,500,000
Unsecured promissory note | TheraCour Pharma Inc | Related party |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate per annum (as a percent) |  |  |  | 12.00% |  |  |  |  |  |  |  |  |
Series A Preferred stock | TheraCour Pharma Inc |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares upon principle of note convertible |  |  |  | 331,859 |  |  |  |  |  |  |  |  |
Debt instrument, conversion stock, par value |  |  |  | $ 0.00001 |  |  |  |  |  |  |  |  |
Series A Preferred stock | TheraCour Pharma Inc | Related party |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of net sales allocated for royalty payments (in percent) |  |  |  |  |  |  | 15.00% |  |  |  |  |  |
Series A Preferred stock | TheraCour Pharma Inc | COVID 19 License Agreement | Related party |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares authorized for license milestone payment |  |  |  |  | 50,000 |  | 100,000 |  |  |  |  |  |
Shares issued for milestone payment |  |  |  |  |  | 50,000 |  |  |  |  |  |  |

X
- Definition Amount for accounts payable offset by advance. + References No definition available. + Details
Name: | nnvc_AccountsPayableOffsetByAdvance
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of clinical trial and other costs accrued + References No definition available. + Details
Name: | nnvc_AccruedClinicalTrialAndOtherCosts
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of the obligations incurred through Clinical trials. Used to reflect the current portion of the liabilities (The amount has been recorded within accrued expenses in the accompanying balance sheet). + References No definition available. + Details
Name: | nnvc_AccruedClinicalTrialCosts
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of the obligations incurred through Clinical trials. Used to reflect the current portion of the liabilities (The amount has been recorded within accrued expenses in the accompanying balance sheet). + References No definition available. + Details
Name: | nnvc_ClinicalTrialRelatedToOtherCostsCharges
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of milestone payment due. + References No definition available. + Details
Name: | nnvc_MilestonePaymentAmountDue
Namespace Prefix: | nnvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of shares authorized for license milestone payment. + References No definition available. + Details
Name: | nnvc_NumberOfSharesAuthorizedForLicenseMilestonePayment
Namespace Prefix: | nnvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of direct costs. + References No definition available. + Details
Name: | nnvc_PercentageOfDirectCosts
Namespace Prefix: | nnvc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty expense calculated as a percentage of net sales. + References No definition available. + Details
Name: | nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments
Namespace Prefix: | nnvc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalties on sales. + References No definition available. + Details
Name: | nnvc_PercentageOfRoyaltiesOnSales
Namespace Prefix: | nnvc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Shares issued during the period for license agreement. + References No definition available. + Details
Name: | nnvc_SeriesPreferredSharesIssuedDuringPeriodForLicenseAgreement
Namespace Prefix: | nnvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of stock issued during period shares new issues principle of note convertible. + References No definition available. + Details
Name: | nnvc_StockIssuedDuringPeriodSharesNewIssuesPrincipleOfNoteConvertible
Namespace Prefix: | nnvc_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details
Name: | us-gaap_AccountsPayableCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_AccountsPayableCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details
Name: | us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective. + References No definition available. + Details
Name: | us-gaap_DebtInstrumentConvertibleStockPriceTrigger
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details
Name: | us-gaap_GainsLossesOnExtinguishmentOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of the cost of borrowed funds accounted for as interest expense for debt. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details
Name: | us-gaap_InterestExpenseDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_LineOfCredit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Date the credit facility terminates, in YYYY-MM-DD format. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_LineOfCreditFacilityExpirationDate1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition The effective interest rate during the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_LineOfCreditFacilityInterestRateDuringPeriod
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of general and administrative expense classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details
Name: | us-gaap_OtherGeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromLinesOfCredit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=nnvc_Dr.AnilDiwanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nnvc_KarveerMeditechPvt.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nnvc_TheracourPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nnvc_Covid19LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=nnvc_UnsecuredPromissoryNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |